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Introduction
HPV (human papillomavirus) infection is the main 
cause of cervical cancer, and infection typically occurs 
through sexual behavior. The prevalence of cervical cancer 
is associated primarily with early sexual experience, 
low income, the number of sexual partners, and sexual 
activity with high-risk men (Deacon et al., 2000); thus, 
the highest prevalence of HPV infection is in individuals 
in their 20s (Dunne et al., 2007). Most HPV infections 
spontaneously resolve within a few months, and 90% 
of infections disappear within 2 years. However, some 
cases of persistent HPV infection result in cervical cancer 
(Koshiol et al., 2008). According to the annual report of 
cancer statistics in Korea, the age-standardized prevalence 
of cervical cancer was reported as 12.3 per 100,000 
people in 2010, which was a decreasing trend from 18.6 
per 100,000 people in 1999 (The Korea Central Cancer 
Registry, 2010). However, the economic burden of HPV 
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Abstract
 Background: After the WHO recommended HPV vaccination of the general population in 2009, government 
support of HPV vaccination programs was increased in many countries. However, this policy was not implemented 
in Korea due to perceived low cost-effectiveness. Thus, the aim of this study was to analyze the cost-utility of 
HPV vaccination programs targeted to high risk populations as compared to vaccination programs for the 
general population. Materials and Methods: Each study population was set to 100,000 people in a simulation 
study to determine the incremental cost-utility ratio (ICUR), then standard prevalence rates, cost, vaccination 
rates, vaccine efficacy, and the Quality-Adjusted Life-Years (QALYs) were applied to the analysis. In addition, 
sensitivity analysis was performed by assuming discounted vaccination cost. Results: In the socially vulnerable 
population, QALYs gained through HPV vaccination were higher than that of the general population (General 
population: 1,019, Socially vulnerable population: 5,582). The results of ICUR showed that the cost of HPV 
vaccination was higher for the general population than the socially vulnerable population. (General population: 
52,279,255 KRW, Socially vulnerable population: 9,547,347 KRW). Compared with 24 million KRW/QALYs 
as the social threshold, vaccination of the general population was not cost-effective. In contrast, vaccination of 
the socially vulnerable population was strongly cost-effective. Conclusions: The results suggest the importance 
and necessity of government support of HPV vaccination programs targeted to socially vulnerable populations 
because a targeted approach is much more cost-effective. The implementation of government support for such 
vaccination programs is a critical strategy for decreasing the burden of HPV infection in Korea. 
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infection-related diseases was reported to be 280 billion 
KRW in 2005 (Shin, 2007). 
Gardasil and Cervarix have been used to prevent 
cervical cancer caused by HPV infection. Gardasil is a 
quadrivalent vaccine that is effective against HPV types 
6, 11, 16, and 18. Cervarix is a bivalent vaccine that is 
effective against HPV types 16, and 18. The efficacy of 
these vaccines is 99% and 95%, respectively. However, 
efficacy is significantly reduced in women with pre-
existing HPV infection (Mao et al., 2006; Villa et al., 2006; 
Ozgul et al., 2011). After the WHO recommended HPV 
vaccination of the general population in 2009, government 
support of HPV vaccination programs was instituted in 
many countries (WHO, 2008; Do et al., 2009; Karadag 
et al., 2014; Yilmazel and Duman, 2014). However, 
programs for the general population were not implemented 
in Korea due to less cost-effective. Due to various 
limitations, previous studies on the cost-effectiveness of 
HPV vaccination in Korea had low accuracy (Shin, 2007; 
Kyu-Tae Han et al
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Marra et al., 2009; Armstrong, 2010). In contrast, other 
studies on the cost-effectiveness of HPV vaccination in 
some countries showed high cost-effectiveness for the 
specific population (Techakehakij and Feldman, 2008; 
Jeurissen and Makar, 2009).
According to a study by Wilkinson, the home 
environment was among environmental risk factors that 
most influenced to the problem behavior of adolescents. 
In particular, the structural aspects such as the absence of 
one or both parents instead, low socio-economic status, 
etc., and functional aspects such as psychological distance 
between parent and child, and poor parenting attitudes 
were reported as major factors for problem behaviors in 
adolescents (Wilkinson, 1973). In addition, the results 
of previous studies showed that the population most 
vulnerable to HPV infection had been exposed to many 
risk factors including low income, and low education level 
(Bambra, 1999; Nyari et al., 2001; Frohlich and Potvin, 
2008; Zhang et al., 2012). Thus, the aim of this study 
was to include these additional factors in our analysis of 
the cost-effectiveness for an HPV vaccination program 
targeted to high risk populations, as compared to the 
general population.
Materials and Methods
Study population
This study used a novel approach of focusing on 
adolescents from broken families and low-income families 
as the socially vulnerable population. These subjects were 
chosen because of the high probability of problem and 
risky behavior that could lead to HPV infection.
Standardized prevalence rate 
The standardized prevalence of HPV infection in the 
total population was calculated using the disease statistics 
provided by the HIRA (Health Insurance Review and 
Assessment Service). Subsequently, we calculated the 
odds ratio by adjusting for age, economic status, academic 
records, and survey year in the Korea Youth Risk Behavior 
Web-based Survey (KYRBWS). These data then were 
used to calculate the standardized prevalence in the general 
and socially vulnerable populations (Health Insurance 
Review & Assessment Service, 2010-2012; Korea Centers 
for Disease Control and Prevention, 2010-2012).
Cost 
The medical costs of HPV-infected patients included 
the vaccine cost as well as the costs imposed by those 
not vaccinated. Health insurance claims data provided 
by the National Evidence-based Healthcare Collaborating 
Agency were used to calculate the non-medical costs of 
HPV-infected patients. These costs included administration 
costs and transportation costs (National Evidence-based 
Healthcare Collaboratiing Agency, 2012). 
Vaccination rates
It is inevitable that incomplete vaccination occurs at a 
certain rate because complete HPV vaccination consists 
of a series of three vaccinations. Thus, the data were 
stratified according to each stage of vaccination; the 
data used were provided by the National Evidence-based 
Healthcare Collaborating Agency (National Evidence-
based Healthcare Collaboratiing Agency, 2012). 
Vaccine efficacy
Within the group of sexually active individuals, we 
included in the definition of incomplete vaccination 
individuals who engaged in potentially risky sexual 
activity before vaccination. Then, the calculation for 
vaccine efficacy was stratified by age (Korea Centers for 
Disease Control and Prevention, 2010-2012). 
QALYs
Because the data from the Korea National Health 
and Nutrition Examination Survey appeared to be an 
overestimation of the QALY in Korea, we used the 
U.S. estimation of QALYs for analysis. QALYs for the 
economic evaluation of HPV vaccination were determined 
for both the general population and the social vulnerable 
population (Elbasha et al., 2007; Basu et al., 2008).
Incremental cost-utility ratio (ICUR)
In order to determine the ICUR, we set the study 
population to 100,000 individuals for the simulation study, 
then standard prevalence rates, cost, vaccination rates, 
vaccine efficacy, and QALYs were applied to the analysis 
(Hassan et al., 2008). 
In performing the analysis, the following assumptions 
were made. First, vaccination was assumed all members 
of each population. Second, vaccination efficacy 
was evaluated according to vaccine type, incomplete 
vaccination, and whether individuals were sexually active. 
Third, the ratio of vaccine type administered was assumed 
to be 1:1. Fourth, the income threshold was set to 24 
million KRW. If the ICUR of vaccination was lower than 
24 million KRW, the results indicated cost-effective for 
vaccination of that population. Finally, a 3% discount rate 
for vaccine cost was applied to the analysis for each year.
Sensitivity analysis
We wanted to determine if providing vaccines at 
a discounted cost would affect the cost-effectiveness 
of vaccinating the general and the target populations. 
Incremental discounted costs for vaccination (33%, 55%, 
and 66%) were applied to the analysis. From these data, the 
incremental cost-utility ratio was determined (Figure 1).
Results 
The odds ratio for sexual activity was calculated 
by adjusting age, economic status, academic records, 
and survey year for the data from the Korea Youth Risk 
Behavior Web-based Survey. The socially vulnerable 
population had a higher odds ratio than the general 
population (OR of the socially vulnerable population: 
4.264, Ref=general population).
Applying the odds ratio to the statistics of disease from 
the HIRA, the standardized prevalence of HPV infection 
in the general and socially vulnerable populations was 
calculated (Table 1). 
The analysis of vaccination efficacy (see Table 2), 
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taking into account age at first sexual experience, showed 
that the vaccination efficacy in the general population was 
higher than in the socially vulnerable population. (General 
population: 88.0%, Socially vulnerable population: 84.0%. 
The cost for vaccination was calculated by applying 
the costs reported in study of the National Evidence-
based Healthcare Collaborating Agency to vaccination 
rates. Costs were calculated for the target population of 
100,000 people (Medical cost: 48,716,167,500 KRW, 
Non-medical cost: 4,577,017,680 KRW). To evaluate the 
efficacy of HPV vaccination, QALYs for each population 
were calculated using the QALYs of HPV-related disease. 
In the socially vulnerable population, QALYs gained 
through HPV vaccination were higher than that of 
general population (General population: 1,019, Socially 
vulnerable population: 5,582; Table 3). 
ICUR was determined by adjusting for standardized 
prevalence rates, vaccination efficacy, QALYs, and cost. 
The results showed that the cost of HPV vaccination 
was higher for the general population than the socially 
vulnerable population. (General population: 52,279,255 
Table 1. Standardized Prevalence Rates of Disease Associated with HPV (Unit: Patients Per 100,000 People)
Study Population Age Cervical CIN Ⅰ CIN Ⅱ CIN Ⅲ
  Cancer Mild Moderate Severe Carcinoma
   Cervical dysplasia Cervical dysplasia Cervical dysplasia in situ of cervix uteri
General Population 10-19 0.2 5.3 1.2 0.6 0.3
 20-29 12.8 216.8 63.3 37.6 62.1
 30-39 72 296.6 97.2 74.4 188.3
 40-49 160.5 304.9 92.7 67 208.4
 50-59 230.8 206.9 61 44.8 144.1
 60-69 256.9 102.9 38.2 31.4 106.5
 70-79 193 36.9 17.7 16.9 57.6
 80- 65.2 4.1 3 3 8
Socially vulnerable population 10-19 0.82 17.32 3.93 1.86 0.88
 20-29 52.75 704.09 205.57 122.03 201.84
 30-39 297.78 963.6 315.64 241.65 611.59
 40-49 663.54 990.5 301.11 217.64 677.06
 50-59 954.13 672.13 198.06 145.45 468.15
 60-69 1,061.90 334.4 123.99 101.97 345.8
 70-79 797.85 119.78 57.44 54.76 186.97
 80- 269.55 13.16 9.65 9.65 25.83
Table 2. Vaccination Efficacy by Population
Vaccination  Percentages Percentages
timing (Age) of general  of socially 
 population vulnerable population
11 99.03% 98.78%
12 97.74% 97.09%
13 97.81% 97.11%
14 97.91% 97.19%
15 98.31% 97.68%
16 98.85% 98.39%
17 99.03% 98.63%
18 99.37% 99.11%
Vaccination Efficacy 88.04% 83.99%Figure 1. Flow Chart of Study
Figure 2. Sensitivity Analysis for HPV Vaccination Cost 
by Discounted Level (Unit: KRW/QALYs)
KRW, Socially vulnerable population: 9,547,347 KRW; 
Table 4). Compared with 24 million KRW/QALYs as the 
social threshold, vaccination of the general population had 
no cost-effective. In contrast, vaccination of the socially 
vulnerable population had strong cost-effective.
After assuming discounted the vaccination cost, 
the result of study analyzed by applying discounted 
vaccination cost to the sensitivity analysis. In the 
sensitivity analysis, vaccination of the general population 
had cost-effective only at the 66% discounted vaccination 
cost level. In the case of the socially vulnerable population, 
discounted vaccination costs had cost-effective at all 
discount levels evaluated (Figure 2).
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Table 4. Increment Cost-Utility Ratio for HPV Vaccination by Population (Unit: KRW, KRW/QALYs)
Target Population Medical Cost Non-medical Cost Total Cost QALYs  A-B ICUR
    Not Vaccination  Vaccination   
    (B) (A)  
General Population    3,121,300 3,122,319 1,019 52,279,255
 48,716,167,500 4,577,017,680 53,293,185,180
Socially Vulnerable Population    3,115,811 3,121,393 5,582 9,547,347
Table 3. The Costs of HPV Vaccination and QALYs for Economic Evaluation (Unit: KRW, QALYs)
Cost
   Medical Cost       Vaccine Cost Vaccination Rates Vaccinated People Total Vaccination Cost Total Cost
  165,000 1/3  dose schedule of vaccination 5.14% 5,140 848,100,000 48,716,167,500
   2/3  dose schedule of vaccination 8.53% 8,530 2,814,900,000 
   3/3  dose schedule of vaccination 86.33% 86,330 42,733,350,000 
   Total 100% 100,000 46,396,350,000 
   Loss of Cost (5%)   2,319,817,500
   Non-medical cost Details Total Cost
  Administration Cost Personnel expenses Communication cost (3 times/case) Other indirect costs 4,577,017,680
  Transportation costs Average cost*1.5 (Subjects and their parents)
QALYs Disease General population Socially vulnerable population
 Cervical Cancer 240 1,380
 CIN Ⅰ 108 620
 CIN Ⅱ 276 1,581
 CIN Ⅲ 534 3,065
 QALYs Increase for Vaccination (A) 1,158 6,646
 Non-immunization among vaccinated people (B) 138 1,064
 Total QALYs Increase (A-B) 1,019 5,582
*QALYs: CINⅠ(0.910), CINⅡ/Ⅲ(0.870), Cervical Cancer(0.700)
Discussion
Many previous studies for HPV-related disease 
measured the cost-effectiveness of vaccine programs 
targeted to the general population, and those studies found 
that vaccination programs for the general population had 
not cost-effective. However, the studies were limited by 
the expensive vaccination cost and limits of efficacy. 
The present study analyzed the cost-effectiveness of 
vaccination programs targeted to a socially vulnerable 
population versus the general population.
The result of our analysis showed that HPV vaccination 
programs targeted to the socially vulnerable population 
had high cost-effective, unlike the lack of cost-effective for 
the general population. By sensitivity analysis, the general 
population had cost-utility only at a 66% discounted 
vaccination cost. The socially vulnerable population had 
absolute cost-effective at all discount levels tested.
Of course, some studies about HPV vaccination 
of targeted groups have demonstrated economic value 
(Aponte-Gonzalez et al., 2013; Demarteau et al., 2013; 
Drolet et al., 2013; Elbasha et al., 2009; English et al., 
2013; Fesenfeld et al., 2013; Kim et al., 2007; Natunen et 
al., 2013; Turner et al., 2013; Woertman and van der Wilt, 
2013). However, the present study also considered the 
home environment when defining the socially vulnerable 
group. Thus, our findings include another important factor 
for the target group when evaluating the economic value 
of HPV vaccination.
This study has some limitations. First, we used 
estimated data for the simulation study because we did 
not have access to actual numbers. Therefore, the results 
of this study can provide only trends about the economic 
value of HPV vaccination. Next, we did not consider 
medical costs incurred because of disease related to HPV 
infection. However, we applied the same assumptions 
to each population that was evaluated. Our approach 
provides a method to determine a reasonable estimate of 
the economic burden of HPV vaccination. In addition, this 
study had to use U.S. QALYs because exact data about 
QALYs in Korea is lacking.
In spite of these limitations, our results suggest the 
importance and cost-effectiveness for national support 
of HPV vaccination of socially vulnerable populations. 
Through the implementation of a national policy to support 
vaccination of socially vulnerable populations rather than 
the general population, we expect to see a decrease in the 
economic burden caused by HPV infections (Liao et al., 
2009; Demarteau et al., 2012; da Fonseca et al., 2013). 
Of course, it is difficult to determine the actual economic 
value of HPV vaccination from the results of this study; 
thus, further studies should be undertaken. Targeting 
vaccination programs to specific populations at high risk 
is a new alternative for reducing the economic burden due 
to HPV infection.
In conclusion, the results of this study suggest the 
importance and necessity of government support of HPV 
vaccination programs targeted to socially vulnerable 
populations because a targeted approach is much more 
cost-effective than vaccinating the general population. 
The implementation of government support for such 
vaccination programs is a critical strategy for decreasing 
the burden of HPV infection in Korea. 
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